United States set
language
Menu Shopping cart $0 Search
Advanced Search
You are here:   Home Scientific References

Scientific References

BioVendor collects scientific publications where the use of our immunoassays, recombinant proteins, and monoclonal and polyclonal antibodies is cited.

Filter references:
Find Product:

  • References to Total GLP-1-HS ELISA Kit

    • Nauck MA, Walberg J, Vethacke A, El-Ouaghlidi A, Senkal M, Holst JJ, Gallwitz B, Schmidt WE, Schmiegel W. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept. 2004 Apr 15;118(1-2):89-97. doi: 10.1016/j.regpep.2003.11.003. PubMed PMID: 14759561. See more on PubMed
    • Näslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, Hellström PM. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr. 2004 Mar;91(3):439-46. doi: 10.1079/BJN20031064. PubMed PMID: 15005830. See more on PubMed
    • Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev. 2002 Nov-Dec;18(6):430-41. doi: 10.1002/dmrr.328. PubMed PMID: 12469357. See more on PubMed
    • Vella A, Shah P, Basu R, Basu A, Holst JJ, Rizza RA. Effect of glucagon-like peptide 1(7-36) amide on glucose effectiveness and insulin action in people with type 2 diabetes. Diabetes. 2000 Apr;49(4):611-7. doi: 10.2337/diabetes.49.4.611. PubMed PMID: 10871199. See more on PubMed
    • Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15(11):937-45. doi: 10.1002/(SICI)1096-9136(1998110)15:11<937::AID-DIA701>3.0.CO;2-0. PubMed PMID: 9827848. See more on PubMed
    • Asarian L, Corp ES, Hrupka B, Geary N. Intracerebroventricular glucagon-like peptide-1 (7-36) amide inhibits sham feeding in rats without eliciting satiety. Physiol Behav. 1998 Jun 1;64(3):367-72. doi: 10.1016/s0031-9384(98)00089-4. PubMed PMID: 9748106. See more on PubMed
    • Orskov C, Rabenhøj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994 Apr;43(4):535-9. doi: 10.2337/diab.43.4.535. PubMed PMID: 8138058. See more on PubMed
    • Mojsov S, Kopczynski MG, Habener JF. Both amidated and nonamidated forms of glucagon-like peptide I are synthesized in the rat intestine and the pancreas. J Biol Chem. 1990 May 15;265(14):8001-8. PubMed PMID: 1692320. See more on PubMed
    • Yanaihara N. [Recent advances in gastrointestinal hormones]. Hum Cell. 1990 Mar;3(1):1-8. PubMed PMID: 1707301. See more on PubMed
    • Heinrich G, Gros P, Habener JF. Glucagon gene sequence. Four of six exons encode separate functional domains of rat pre-proglucagon. J Biol Chem. 1984 Nov 25;259(22):14082-7. PubMed PMID: 6094539. See more on PubMed

  • References to t-PA Human ELISA

    • Gurbuz Y, Ozturk B, Tutuncu EE, Sencan I, Cicek Senturk G, Altay FA. Evaluation of Prognostic Values of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 in Crimean-Congo Hemorrhagic Fever Patients. Jundishapur J Microbiol. 2015 Oct 20;8(10):e26514. doi: 10.5812/jjm.26514. eCollection 2015 Oct. PubMed PMID: 26587219. PubMed CentralPMCID: PMC4644349. See more on PubMed

  • References to Urine CartiLaps® ELISA (CTX-II)

    • Henrotin Y, Bannuru R, Malaise M, Ea HK, Confavreux C, Bentin J, Urbin-Choffray D, Conrozier T, Brasseur JP, Thomas P, Hick AC, Marinello A, Giordan N, Richette P. Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study. BMC Musculoskelet Disord. 2019 Jun 18;20(1):293. doi: 10.1186/s12891-019-2667-0. PubMed PMID: 31215422. PubMed CentralPMCID: PMC6580647. See more on PubMed

  • References to Urine Pre-Clinical CartiLaps® ELISA (CTX-II)

    • Henrotin Y, Bannuru R, Malaise M, Ea HK, Confavreux C, Bentin J, Urbin-Choffray D, Conrozier T, Brasseur JP, Thomas P, Hick AC, Marinello A, Giordan N, Richette P. Hyaluronan derivative HYMOVIS® increases cartilage volume and type ii collagen turnover in osteoarhritic knee: data from MOKHA study. BMC Musculoskelet Disord. 2019 Jun 18;20(1):293. doi: 10.1186/s12891-019-2667-0. PubMed PMID: 31215422. PubMed CentralPMCID: PMC6580647. See more on PubMed

  • References to Urocortin 2 Mouse ELISA

    • Chen A, Vaughan J, Vale WW. Glucocorticoids regulate the expression of the mouse urocortin II gene: a putative connection between the corticotropin-releasing factor receptor pathways. Mol Endocrinol. 2003 Aug;17(8):1622-39. doi: 10.1210/me.2003-0054. Epub 2003 May 22. PubMed PMID: 12764078. See more on PubMed
    • Chen A, Blount A, Vaughan J, Brar B, Vale W. Urocortin II gene is highly expressed in mouse skin and skeletal muscle tissues: localization, basal expression in corticotropin-releasing factor receptor (CRFR) 1- and CRFR2-null mice, and regulation by glucocorticoids. Endocrinology. 2004 May;145(5):2445-57. doi: 10.1210/en.2003-1570. Epub 2004 Jan 21. PubMed PMID: 14736736. See more on PubMed
    • Bale TL, Hoshijima M, Gu Y, Dalton N, Anderson KR, Lee KF, Rivier J, Chien KR, Vale WW, Peterson KL. The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci U S A. 2004 Mar 9;101(10):3697-702. doi: 10.1073/pnas.0307324101. Epub 2004 Feb 27. PubMed PMID: 14990799. PubMed CentralPMCID: PMC373525. See more on PubMed
    • Brar BK, Jonassen AK, Egorina EM, Chen A, Negro A, Perrin MH, Mjøs OD, Latchman DS, Lee KF, Vale W. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology. 2004 Jan;145(1):24-35; discussion 21-3. doi: 10.1210/en.2003-0689. Epub 2003 Sep 11. PubMed PMID: 12970163. See more on PubMed
    • Hinkle RT, Donnelly E, Cody DB, Bauer MB, Isfort RJ. Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function. Endocrinology. 2003 Nov;144(11):4939-46. doi: 10.1210/en.2003-0271. Epub 2003 Jul 31. PubMed PMID: 12960070. See more on PubMed
    • Tanaka Y, Makino S, Noguchi T, Tamura K, Kaneda T, Hashimoto K. Effect of stress and adrenalectomy on urocortin II mRNA expression in the hypothalamic paraventricular nucleus of the rat. Neuroendocrinology. 2003 Jul;78(1):1-11. doi: 10.1159/000071700. PubMed PMID: 12869794. See more on PubMed
    • Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW, Sawchenko PE. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2843-8. doi: 10.1073/pnas.051626398. PubMed PMID: 11226328. PubMed CentralPMCID: PMC30227. See more on PubMed